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High-mobility group protein box-1 (HMGB1) is a proinﬂammatory involved in many inﬂammatory diseases. However, its roles
in intracerebral hemorrhage (ICH) remain unknown. The purpose of this study was to examine the correlation between changes
in serum levels of HMGB1 following acute ICH and the severity of stroke as well as the underlying mechanism. Changes in serum
levelsofHMGB1in60consecutivepatientswithprimaryhemisphericICHwithin12hoursofonsetofsymptomsweredetermined.
The correlation of HMGB1 with disease severity, IL-6, and TNF-α was analyzed. Changes in HMGB1 levels were detected with
ELISA and Western blot. Compared with normal controls, patients with ICH had markedly elevated levels of HMGB1, which was
signiﬁcantly correlated with the levels of IL-6 and TNF-α, NIHSS score at the 10th day, and mRS score at 3 months. In comparison
with the control group, the levels of HMGB1 in the perihematomal tissue in mice with ICH increased dramatically, peaked at 72
hours, and decreased at 5 days. Meanwhile, heme could stimulate cultured microglia to release large amounts of HMGB1 whereas
Fe
2+/3+ ions failed to stimulate HMGB1 production from microglia. Our ﬁndings suggest that HMGB1 may play an essential role
in the ICH-caused inﬂammatory injury.
1.Introduction
A growing body of evidence has shown that inﬂammatory
responses play an important role in ICH-induced injury [1–
3]. Hematoma components and metabolites of red blood
cells in ICH can provoke brain tissues to produce inﬂam-
matory response, causing cerebral edema and aggravating
neurological deﬁcits [4]. In addition, ICH can also elicit
strong systemic inﬂammatory responses, resulting in abun-
dant release of inﬂammatory factors such as IL-6 and TNF-
α, further exacerbating neurological deﬁcits [2]. However,
the mechanism responsible for ICH-induced inﬂammatory
responses has not been fully understood.
HMGB1 is a nuclear factor and a DNA-binding protein
[5–7]. Recently, an increasing number of studies have
shown that it is also a proinﬂammatory factor capable of
stimulating the production of other inﬂammatory factors
and plays an important role in sepsis and cerebral ischemia-
caused inﬂammatory injury [8–10]. However, its role in
inﬂammatory injury resulting from ICH remains largely
undeﬁned. A previous study [11] showed that levels of
HMGB1 in the peripheral blood and cerebrospinal ﬂuid
(CSF) in subarachnoid hemorrhage (SAH) increased signif-
icantly and were positively associated with disease severity.
Similarly,ourpreviousstudy[12]showedthattheexpression
of Toll-like receptor 4 (TLR4), a receptor of HMGB1, in
the perihematomal tissue in ICH was signiﬁcantly elevated
and exhibited a signiﬁcant positive correlation with disease
severity.Therefore,wespeculatethatserumlevelsofHMGB1
may also increase dramatically following ICH. The aim of
the present study was to examine the association between
changes in serum levels of HMGB1 following acute ICH and2 Mediators of Inﬂammation
stroke severity and investigate the underlying mechanism,
in an attempt to shed light on the role of HMGB1 in ICH-
caused inﬂammatory injury.
2.MaterialsandMethods
2.1. Subjects. This prospective study included 65 patients
with acute ICH admitted to the Stroke Center of our hospital
w i t h i n1 2h o u r so fs y m p t o mo n s e t( m e a n :7 . 4h o u r s )f r o m
January2009toMarch2010.Patientselectionwasperformed
basedonapreviousstudy[13]andthecriteriarecommended
by the Forth Chinese National Meeting for Cerebrovascular
Disease (1996). Exclusion criteria were as follows: (1) patient
age <18 years; (2) patients who underwent surgery after
admission; (3) patients who were in coma or died on
admission or 48 hours after admission; (4) patients with
hemorrhage due to brain tumor, trauma, drug abuse, coag-
ulation abnormalities, anticoagulation therapy, or vascular
malformations; (5) obvious inﬂammatory conditions (e.g.,
infectious disease, systemic lupus erythematosus, rheuma-
tism, and rheumatoid disease) within the half year before
enrolment; hospital-acquired infection (conﬁrmed by the
patient’s symptoms and laboratory ﬁndings); acute myocar-
dial infarction (diagnosed according to the patient’s symp-
toms and electrocardiographic ﬁndings); acute ischemia
of liver (conﬁrmed by liver function test); autoimmune
disease (diagnosed according to the patient’s symptoms
and positive autoimmune antibodies); patients who took
glucocorticosteroids or immunodepressants; patients who
were incompliant to the study protocol or could not undergo
all the tests required by the study. A total of ﬁve patients
were excluded from the study, including three patients who
died and two who were lost to follow-up. The remaining 60
patients with acute ICH were included for analysis.
A total of 41 healthy people who underwent regular
physical examinations at our hospital were included in
the control group. The controls were matched with the
patients in terms of age and gender, and they did not
have acute ischemia of the heart, peripheral tissues, or
brain within 12 months before enrolment (see Table 1).
Signed informed consent was obtained from all the study
subjects,andthestudyprotocolwasapprovedbytheMedical
Ethics Committee of the hospital. Peripheral leukocytes and
platelets were counted.
All patients were admitted at an acute stroke unit and
treated according to the guidelines of the European Stroke
Initiative [14]. The patients underwent head CT examina-
tions on admission, 72 hours and 7 days after admission,
respectively. Size of hematoma and peripheral hypodensity
volume of ICH were measured using the formula of the
perpheral, and edema volume was calculated by subtracting
the volume of the ICH from that of the total lesion.
Mass eﬀect was considered when ventricular asymmetry or
shifting of the midline structure was observed. All CT scans
were centrally evaluated by an investigator who was masked
to clinical data.
The National Institutes of Healthy Stroke Scale (NIHSS)
was used to rate the severity of stroke [15], and modiﬁed
Rankin Scale (mRS) scores were used to assess the functional
status of patients at 3 months after the onset of stroke, and
poor outcome was deﬁned as modiﬁed rankin scale score >2.
A total of 10mL of blood sample was drawn from the
median cubital vein on admission. Serum were isolated at
roomtemperature.Serumsampleswerestored −80◦Cbefor e
measurement.
2.2. HMGB1 ELISA Assay. An ELISA kit for human HMGB1
assay (R&D Systems Inc. MN, USA) was used to determine
the concentration of HMGB1. The detection threshold of
this assay is <1ng/mL. The between-assay coeﬃcient of
variations is <10%. Serum levels of TNF-α and IL-6 were
determined by ELISA according to the instructions provided
with the kits (Beijing Jingmei Co. China).
2.3. HMGB1 Western Blot Assay. Proteins were prepared
fromserumandperihematomalbraintissue.Brieﬂy,proteins
were separated by SDS-polyacrylamide gel electrophoresis
and transferred onto Hybond ECL membranes (Amersham
Pharmacia). The ECL membranes were incubated with the
primary antibodies including mouse antihuman HMGB1
(for HMGB1 assay in serum, 1:1000, Santa Cruz) or
rabbit antimouse HMGB1 (for HMGB1 assay in brain
tissue, 1:5000, Santa Cruz), followed by incubation with
peroxidase-conjugated secondary antibodies (1:2000, Jing-
mei, China). The signals were detected with ECL system
(Amersham Pharmacia). The same membranes were probed
with antibody for glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) after being washed with stripping buﬀer.
The signals were quantiﬁed by scanning densitometry and
computer-assisted image analysis.
2.4. Mouse ICH Model. C57BL/6 mice (male, 10 weeks old,
weighting 20 to 25g) in our laboratory were employed
with ICH model. The ICH model was established in mice
according to our previous study and a previously described
method [12, 16]. Brieﬂy, anesthesia was induced in mice
by intraperitoneal injection of chloral hydrate (40mg/kg).
Subsequently, 25μl of non-anticoagulated blood was drawn
from the tail vein and injected into the right caudate nucleus
and putamen under the guidance of a stereotactic device
(Stoelting Co., US). The sham-operated group was injected
25μl of normal saline (0.9%). The needle hole left by the
procedure was sealed with bone wax and the incision was
sutured. Mice were randomized into ICH group (n =
15) and sham-operated group (n = 15). After successful
modeling, the mice were sacriﬁced by cervical dislocation at
24 hours, 48 hours, 72 hours, and 5 days. One hundred mg
of perihematomal brain tissue were collected and stored at
−80◦C.Aportionofthetissuesamplewashomogenized,and
the resultant supernatant was detected with ELISA assays.
Another portion of the stored sample was used for protein
extraction and subsequent Western blotting.
2.5. Microglia Culture and Stimulation. For primary
microglial culture, cells were dissociated from the cerebral
hemispheres of 1- to 2-days postnatal mice (C57BL/c mice,Mediators of Inﬂammation 3
Table 1: Clinical, biochemical, and radiological characteristics by subjects.
Control (n = 41) ICH P-value
Good outcome (mRS, 0–2), n = 31 Poor outcome (mRS, 3–6), n = 29
Age, yr 63.2 (9) 65.4 (8) 67.4 (10) NS
Sex (M/F, %) 61.4/ 59.8 65.3 NS
Time from onset to admission, hr 6.5 (3.2–9.5) 5.9 (2.6–8.7) NS
History of vascular risk factors (%)
Hypertension 42.1 75.5∗∗ 72.6∗∗ .0003
Diabetes 23.8 26.5 24.7 NS
Smoking habit (current) 16.5 11.7 15.3 NS
Alcohol consumption 18.7 21.6 26.8 NS
Prior medication with
Lipid-lowering drugs 26.6 18.9 28.5 NS
Platelet inhibitors 33.0 28.6 31.4 NS
Vital signs
Systolic blood pressure, mmHg 178 (32) 176 (28) NS
Diastolic blood pressure, mmHg 101 (16) 98 (22) NS
Maximal SBP in 24 hr, mmHg 198 (26) 192 (24) NS
Maximal DBP in 24 hr, mmHg 110 (12) 108 (9) NS
Body temperature, (
◦C) 36.5 (0.62) 36.2 (0.81) NS
Glasgow scale at baseline 15 (14-15) 12 (10–14) <.001
NIHSS at 10 days 9 (5–15) 21 (16–24) <.001
mRS at 3 month 1.8 (0–2) 4 (3–6) <.001
Neuroimaging ﬁndings
Topography, % lobar 45.2 42.8 NS
ICH volume at baseline, mL 14.8 (6.8–22.0) 34.2 (15.0–52.4) <.001
Edema volume at baseline, mL 3.2 (1.2–9.0) 12.0 (5.2–14.8) <.01
ICH growth at 72 hours, ratio 0.08 (0.0–0.41) 0.11 (0.02–0.46) NS
I C Hg r o w t ha t7d a y s ,r a t i o −0.32 (−0.55–0.02) 0.01 (−0.19–0.29) <.01
Edema growth at 72 hours, ratio 0.65 (0.03–4.32) 0.88 (0.46–3.34) NS
Edema growth at 7 days, ratio 0.94 (0.00–3.10) 1.21 (0.12–2.54) NS
Intraventricular bleeding, % 11.5 53.4 <.001
Mass eﬀect, % 21.0 68.5 <.001
Laboratory parameters
Serum glucose, mg/dL 125 (23) 117 (36) NS
Platelet count, ×1000/mmc 226 (72) 241 (69) NS
Leukocyte count, ×1000/mmc 7.8 (2.0) 8.1 (1.8) NS
Plasma ﬁbrinogen, mg/dL 455 (120) 447 (116) NS
IL-6, pg/mL 102.6 (35.6) 184.2 (38.4) <.01
TNF-α, pg/mL 54.3 (15.2) 95.3 (18.5) <.05
Values are presented as proportions, mean (SD), or median (quartiles). CT was performed in 63 patients at 72 hours and 7 days. Reason to not perform
followup CT were death in 2 patients at 72 hours. DBP: diastolic blood pressure; SBP: systolic blood pressure; NIHSS: National Institute of Health Stroke
Scale; mRS: modiﬁed Rankin scale; mmc: cubic millimeter. ∗∗P<. 01 versus control.
10 weeks old, weighting 20 to 25g) brains and seeded into a
6-well plate at a density of 1 × 106/mL with DMEM (Sigma,
St. Louis, MO) containing 10% FBS (Hyclone, Logan, UT).
Culture media were changed twice per week for 2 weeks,
and then microglia were detached by mild shaking and
ﬁltered through a nylon mesh to remove astrocytes. After
centrifugation at 1000×g for 10 minutes, the cells were
resuspended in a fresh DMEM supplemented with 10% FBS
a n dp l a t e da taﬁ n a ld e n s i t yo f4× 104/mL cells on a 24-well
culture plate. The following day, cells were subjected to the
experiments. The microglial cultures used were >95% pure.
Microglia cultures were stimulated with various con-
centrations of heme (0–30μM), FeCl3 and FeSO4 (30μM)
for various time periods according to a method previously
described [17]. After discarding the culture supernatant,
fresh culture medium was added to the microglia. The cells
were cultured for another 12 hours before collection of the
supernatant for HMGB1 determination.4 Mediators of Inﬂammation
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Figure 1: Serum level of HMGB1 increased signiﬁcantly in patients
with acute ICH. Data are presented as mean ± standard deviation.
(a) ELISA assay of the changes of HMGB1 serum levels in patients.
(b) A representative picture of Western blot assay showing the
changes of HMGB1 serum levels in patients. GAPDH was chosen
as the internal control. The changes of HMGB1 were expressed as
the ratio of the optical density values of HMGB1 band to the optical
density values of GAPDH band. ∗∗versus control; P<. 01; ##versus
good outcome group; P<. 01.
2.6.StatisticalAnalysis. Continuousvariableswereexpressed
as mean ± (SD) or median and quartiles and compared by
Student’s t- or the Mann-Whitney tests as appropriate. The
categoricalvariableswerereportedascountsandpercentages
a n da n a l y z e dw i t ht h eχ2 test. Spearman’s correlation coef-
ﬁcients were computed for evaluating associations among
parameters: HMGB1, NIHSS scores, mRS scores, IL-6, and
TNF-α. SPSS11.5 software was used in all statistical analyses.
Values of P<. 05 were considered statistically signiﬁcant in
all tests.
3. Results
3.1. Serum Levels of HMGB1 in Patients with Acute ICH
Increased Markedly and Positively Correlated with the Severity
of Stroke, IL-6, and TNF-α. The demographic data, clinical,
biochemical, and imaging features of the patients are pre-
sented in Table 1. An unfavorable outcome was observed in
48.3% (29/60) of the patients. Higher stroke severity, larger
hematoma volume, larger edema volume, intraventricular
extension, mass eﬀect, and higher baseline IL-6 and TNF-α
were associated with poor clinical outcome. Compared with
the control group, the serum levels of HMGB1 increased
markedly in patients with acute ICH. Signiﬁcant diﬀerence
regarding HMGB1 serum levels was noted among patients
with diﬀerent outcomes. Patients with a poor outcome had
signiﬁcantly higher serum levels of HMGB1 than patients
with a favorable outcome (221.4 ± 49.5 versus 114.6 ±
32.6; P<. 001). As shown in Figure 1, the higher the
levels of HMGB1, the worse the outcome a patient would
have. Correlation analysis showed that the baseline level
of HMGB1 was signiﬁcantly positively correlated with the
baseline levels of IL-6 (r = 0.732; P<. 001) and TNF-a
(r = 0.620; P<. 01). Moreover, the correlation analysis also
revealed that the baseline level of HMGB1 was signiﬁcantly
positively correlated with NIHSS score at 10 days (r = 0.845;
P<. 001) and mRS score at 3 months (r = 0.776; P<. 0001).
These results show that the elevation of HMGB1 serum
levels in patients with acute ICH is signiﬁcantly positively
correlated with the severity of stroke.
3.2. HMGB1 Levels in the Perihematomal Brain Tissue in
Mice with ICH were Signiﬁcantly Elevated. Previous studies
have established that acute ICH can lead to potent systemic
inﬂammatory responses and production of large quantities
of inﬂammatory factors. The ﬁndings above suggest that
largeamountsofHMGB1arepresentintheperipheralblood
of patients with acute ICH. Nevertheless, it remained to
be determined whether the hematoma developed following
ICH could stimulate the generation of HMGB1 in the
perihematomal brain tissue. Accordingly, an ICH model
was established in mice and changes in HMGB1 levels in
the perihematomal brain tissue at various time points after
ICH were examined with ELISA and Western blot assays.
The results are shown in Figure 2. Compared with the
control group, HMGB1 levels in the perihematomal brain
tissue increased dramatically, peaked at 72 hours (352.4 ±
38.7ng/mL), and started to decrease (154.2 ± 19.8ng/mL) at
5 days. These results indicate that the hematoma developed
following ICH stimulates the production of HMGB1 in the
perihematomal brain tissue.
3.3. Heme Could Stimulate the Secretion of HMGB1 by
Cultured Microglia. Our results above demonstrated that the
hematoma developed following ICH stimulated the produc-
tion of HMGB1. However, it remained to be established
what component in the hematoma stimulated brain tissues
to secrete HMGB1. The main blood components, heme
(hemoglobin) and Fe ions, are known to play an important
role in ICH-caused neurological deﬁcits [18]. In addition, a
previous study showed that in some hemorrhagic diseases,
blood components such as heme can cause tissue injury
by stimulating macrophages to release inﬂammatory factors
[17]. Since microglia are the major inﬂammatory cells in
the brain, we examined whether heme and Fe2+/Fe3+, the
two main blood components, could stimulate microglia toMediators of Inﬂammation 5
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Figure 2: The level of HMGB1 increased signiﬁcantly in the
perihematomal tissue of ICH mice. Data are expressed as mean
± standard deviation. (a) ELISA assay of the changes of HMGB1
levels in theperihematomal tissueof ICH mice. (b) Arepresentative
picture of Western blot assay showing the changes of HMGB1 levels
in the perihematomal tissue of mice. GAPDH was chosen as the
internalcontrol.ThechangesofHMGB1wereexpressedastheratio
of the optical density values of HMGB1 band to the optical density
values of GAPDH band. n = 15. ∗∗versus control; P<. 01; ##versus
72 hours; P<. 01.
produce HMGB1. The results are shown in Figure 3.W e
found that heme could provoke signiﬁcant production of
HMGB1 from cultured microglia in a dose- and time-
dependant manner. In contrast, both FeCl3 and FeSO4 failed
tostimulatemicrogliatoproduceHMGB1.Theaboveresults
suggest that heme in the hematoma after ICH can stimulate
surrounding microglia to secrete HMGB1, leading to an
increase in the HMGB1 level in the perihematomal brain
tissue.
4. Discussion
To our knowledge, the present study is the ﬁrst one to
examine the early changes of HMGB1 following acute ICH.
OurresultsshowedthattheserumlevelofHMGB1increased
signiﬁcantly after acute ICH and was signiﬁcantly positively
correlated with stroke severity. Heme can stimulate notable
release of HMGB1 from microglia. Hence, we speculate that
the inﬂammatory factor HMGB1 may exert an important
role in inﬂammation-caused neurological deﬁcits after ICH.
This molecule holds promise as a new early indicator for
evaluating the severity and prognosis of ICH as well as a
novel therapeutic target.
Previous studies have demonstrated that in the early
stages after ICH, potent systemic inﬂammatory responses
are elicited and large amounts of inﬂammatory factors are
released, exacerbating the neurological impairment resulting
from ICH. Our results also showed that the serum level of
HMGB1 increased remarkably in the early stages following
acute ICH (within 12 hours). However, the exact source
of HMGB1 production following ICH remained to be
determined whether it is produced in the peripheral blood,
or it is generated due to the stimulation of the hematoma
on surrounding brain tissues, or it is produced by both
mechanisms? Our study found that HMGB1 levels in the
perihematomal tissue in mice increased signiﬁcantly after
ICH, peaked at 72 hours, and started to drop at 5 days. These
ﬁndings indicate that some components in the hematoma
may stimulate surrounding tissues to produce HMGB1.
Nevertheless, our results did not rule out the possibility that
ICH itself can cause the activation of peripheral inﬂam-
matory cells which will subsequently produce HMGB1.
Further studies into this issue are warranted. Our results
also demonstrated that heme in the hematoma following
ICH could induce microglia to secrete large quantities
of HMGB1, whereas Fe2+/3+ ions did not have such a
stimulatory eﬀect. Therefore, we speculate that heme in the
hematomafollowingICHprovokestheabundantproduction
of HMGB1 from surrounding microglia. However, further
studies are needed to determine the eﬀect that HMGB1 will
cause and the pathways that HMGB1 is involved in.
However, our study also has some limitations. First, the
study was a single-center study including relatively few cases.
Large-scale multicenter studies are needed to conﬁrm the
correlation between HMGB1 changes and the severity of
ICH. Second, our study is only a preliminary investigation
into the possible role of HMGB1 in ICH. More eﬀorts
are justiﬁed to identify the exact role and the underlying
mechanism of HMGB1 involvement in the ICH-caused
inﬂammatory injury.
5. Conclusion
TheserumlevelofHMGB1increasesdramaticallyinpatients
with acute ICH and is signiﬁcantly positively correlated with
theseverityofthestroke.Hemecanstimulatesigniﬁcantpro-
duction of HMGB1 from microglia. Our results suggest that
HMGB1 may play an important role in the inﬂammatory
injury resulting from ICH.6 Mediators of Inﬂammation
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Figure 3: Heme could stimulate the secretion of HMGB1 by cultured microglia. Data are expressed as mean ± standard deviation, n = 6.
(a) Microglia were cultured with various concentrations of heme (0μM, 10μM, 20μM, and 30μM) for 24 hours. Thereafter, the culture
medium was replaced, and the cells were further cultured for 12 hours before collection of the supernatant for ELISA determination of
HMGB1 levels. ∗∗versus 0μM; P<. 01; ##versus 10μM, 20μM; P<. 01. (b) Microglia were treated with 30μMo fh e m ef o rv a r i o u sl e n g t h s
of time (0h, 4h, 8h, 24h, and 48h). Thereafter, the culture medium was replaced, and the cells were further cultured for another 12 hours
before collection of the supernatant for ELISA determination of HMGB1 levels. ∗∗versus 0h; P<. 01; ##versus 4h, 8h, or 24h; P<. 01. (c)
Microglia were treated with 30μMo fh e m e ,3 0μMo fF e C l 3,o r3 0μMo fF e S O 4 for 24 hours. Thereafter, the culture medium was replaced,
and the cells were further cultured for another 12 hours before collection of the supernatant for ELISA determination of HMGB1 levels.
∗∗versus control; P<. 01.
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